TY - JOUR
T1 - Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma
T2 - A study of the Osaka Lymphoma Study Group
AU - Sakane-Ishikawa, Emiko
AU - Nakatsuka, Shin Ichi
AU - Tomita, Yasuhiko
AU - Fujita, Shigeki
AU - Nakamichi, Itsuko
AU - Takakuwa, Tetsuya
AU - Sugiyama, Haruo
AU - Fukuhara, Shirou
AU - Hino, Masayuki
AU - Kanamaru, Akihisa
AU - Soma, Toshihiro
AU - Tsukaguchi, Machiko
AU - Igarashi, Kazuhiko
AU - Kanakura, Yuzuru
AU - Aozasa, Katsuyuki
PY - 2005/12/1
Y1 - 2005/12/1
N2 - Purpose: BACH2, a B-cell-specific transcription repressor, is abundantly expressed in lymphocytes of B-cell lineage as well as B-cell lymphoma cell lines. BACH2 possesses an inhibitory effect on proliferation of Raji cell lines derived from Burkitt's lymphoma. In this study, the prognostic significance of BACH2 expression was examined in diffuse large B-cell lymphoma (DLBCL). Patients and Methods: BACH2 expression was immunohistochemically examined on the paraffin-embedded sections obtained by biopsy from 108 patients (62 males and 46 females; age range, 23 to 85 years) with DLBCL. Staining intensity in the cytoplasm of the tumor cells was categorized as equal to or stronger (level 1) or weaker (level 2) than that in the endothelial cells in the same specimens. Results: Level 1 and 2 expression of BACH2 was found in 32.4% and 67.6% of patients, respectively. Patients with level 1 expression showed significantly better disease-free and overall survival rate than those with level 2 expression (both P < .05). Multivariate analysis revealed BACH2 expression level together with performance status, elevated serum level of lactate dehydrogenase, and treatment response to be independent factors for prognosis of the patients. Conclusion: BACH2 expression level is a useful marker to predict disease-free and overall survival of patients with DLBCL.
AB - Purpose: BACH2, a B-cell-specific transcription repressor, is abundantly expressed in lymphocytes of B-cell lineage as well as B-cell lymphoma cell lines. BACH2 possesses an inhibitory effect on proliferation of Raji cell lines derived from Burkitt's lymphoma. In this study, the prognostic significance of BACH2 expression was examined in diffuse large B-cell lymphoma (DLBCL). Patients and Methods: BACH2 expression was immunohistochemically examined on the paraffin-embedded sections obtained by biopsy from 108 patients (62 males and 46 females; age range, 23 to 85 years) with DLBCL. Staining intensity in the cytoplasm of the tumor cells was categorized as equal to or stronger (level 1) or weaker (level 2) than that in the endothelial cells in the same specimens. Results: Level 1 and 2 expression of BACH2 was found in 32.4% and 67.6% of patients, respectively. Patients with level 1 expression showed significantly better disease-free and overall survival rate than those with level 2 expression (both P < .05). Multivariate analysis revealed BACH2 expression level together with performance status, elevated serum level of lactate dehydrogenase, and treatment response to be independent factors for prognosis of the patients. Conclusion: BACH2 expression level is a useful marker to predict disease-free and overall survival of patients with DLBCL.
UR - http://www.scopus.com/inward/record.url?scp=32944467460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32944467460&partnerID=8YFLogxK
U2 - 10.1200/JCO.2005.02.1626
DO - 10.1200/JCO.2005.02.1626
M3 - Article
C2 - 16258099
AN - SCOPUS:32944467460
VL - 23
SP - 8012
EP - 8017
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 31
ER -
